From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
aINSERM, UMR_S 912, "Sciences Economiques & Sociales de la Santé et Traitement de l'Information Médicale" (SESSTIM) bAix Marseille Université, UMR_S 912, IRD cORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur dAix Marseille University, APHM Sainte-Marguerite, Service d'Immuno-hématologie clinique, Marseille eINSERM SC10-US019, Villejuif fHospices Civils de Lyon, Croix-Rousse Hospital, and INSERM U1052, Lyon, France.
Fabienne
F
Marcellin
Isabelle
I
Fournier
Maria P
MP
Carrieri
Isabelle
I
Poizot-Martin
Laurent
L
Cotte
D000998:Antiviral Agents; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C; D006801:Humans; D011480:Protease Inhibitors; D012254:Ribavirin; D057566:Self Report
D000998:Antiviral Agents; D011480:Protease Inhibitors; D012254:Ribavirin